Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.
Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Akihiko Y, Yamamoto N, Yonemori K. Takeyasu Y, et al. Among authors: yamamoto n. JCO Precis Oncol. 2021 May 3;5:PO.20.00383. doi: 10.1200/PO.20.00383. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036223 Free PMC article.
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Yonemori K, et al. Among authors: yamamoto n. Clin Cancer Res. 2005 Apr 1;11(7):2620-4. doi: 10.1158/1078-0432.CCR-04-1497. Clin Cancer Res. 2005. PMID: 15814642 Clinical Trial.
Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, Ohe Y, Tamura T, Yokota J, Kunitoh H. Shiraishi K, et al. Among authors: yamamoto n, yamamoto s. J Clin Oncol. 2010 Nov 20;28(33):4945-52. doi: 10.1200/JCO.2010.30.5334. Epub 2010 Oct 12. J Clin Oncol. 2010. PMID: 20940192
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Goto Y, Sekine I, Tanioka M, Shibata T, Tanai C, Asahina H, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kikkawa H, Ohki E, Tamura T. Goto Y, et al. Among authors: yamamoto n. Invest New Drugs. 2012 Aug;30(4):1548-56. doi: 10.1007/s10637-011-9715-4. Epub 2011 Jul 13. Invest New Drugs. 2012. PMID: 21748299 Free PMC article. Clinical Trial.
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T. Seki Y, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2012 Apr;69(4):1099-105. doi: 10.1007/s00280-011-1788-4. Epub 2011 Dec 6. Cancer Chemother Pharmacol. 2012. PMID: 22143378 Free PMC article. Clinical Trial.
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T. Asahina H, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2012 Jun;69(6):1477-86. doi: 10.1007/s00280-012-1846-6. Epub 2012 Mar 2. Cancer Chemother Pharmacol. 2012. PMID: 22382879 Free PMC article. Clinical Trial.
6,229 results